Literature DB >> 2095133

[Pharmacokinetics and bioequivalence of two ibuprofen formulations].

G Lenhard1, U Kieferndorf, G Berner, B Engels, U Vögtle-Junkert.   

Abstract

In an open controlled randomized cross-over study in 16 healthy male and female volunteers the bioavailability of ibuprofen (CAS 15687-27-1) sugar-coated tablets (Dolo-Dolgit) was tested versus film-coated tablets containing ibuprofen 600 mg. As it results from the AUC evaluation, the bioavailability of both preparations is very good and almost identical. The ibuprofen concentrations achieved after administration of the test preparation, however, are significantly higher (Cmax = 52.03 micrograms/ml) than those achieved after the reference preparation showing a Cmax of 40.32 micrograms/ml. The tmax of 1.0 h is also significantly shorter than after the reference preparation (tmax = 1.5 h). The t1/2 beta after both the test and the reference preparation is within the known range, i.e. 1.8 h and 1.4 h, respectively. Even in long-term treatment with high dosages, administered 3-4 times daily, there is no accumulation of the active ingredient. Concerning the therapeutic relevance, special attention is to be given to the different time-dependent drug concentrations in the central compartment and in the target compartment. Both the higher Cmax and the shorter tmax achieved following administration of the test preparation are of therapeutic relevance.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2095133

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  3 in total

1.  Application of gastrointestinal simulation for extensions for biowaivers of highly permeable compounds.

Authors:  Marija Tubic-Grozdanis; Michael B Bolger; Peter Langguth
Journal:  AAPS J       Date:  2008-04-02       Impact factor: 4.009

Review 2.  Clinical pharmacokinetics of ibuprofen. The first 30 years.

Authors:  N M Davies
Journal:  Clin Pharmacokinet       Date:  1998-02       Impact factor: 6.447

3.  Equipotent inhibition by R(-)-, S(+)- and racemic ibuprofen of human polymorphonuclear cell function in vitro.

Authors:  M Villanueva; R Heckenberger; H Strobach; M Palmér; K Schrör
Journal:  Br J Clin Pharmacol       Date:  1993-03       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.